Management Team
An experienced team of pharmaceutical professionals from all areas of business expertise lead day-to-day operations at Fidelis.
Our leaders are committed to delivering innovative, high-quality pharmaceutical solutions to fulfill specialized veterinary needs that protect animal welfare and meet the highest standards of care.
MICHAEL WELLS
CYNTHIA DAVIS
Chief Financial Officer and General Manager
STEVEN LEARY, DVM, DACLAM
Steven joined Fidelis after retiring as director of the Division of Comparative Medicine at Washington University in St. Louis. During this 25-year tenure, he provided for the well-being and clinical care of animals at one of the nation’s largest, most complex research institutions and oversaw centralization of the university’s animal care programs and facilities. Previously, Steven also served as a director at the University of Alabama at Birmingham.
Steven earned his DVM degree from Iowa State University and was a postdoctoral fellow in laboratory animal medicine and comparative pathology at Johns Hopkins University. He went on to become a diplomate in the American College of Laboratory Animal Medicine (DACLAM).
To name just a few of his association positions, Steven has served the industry as president of ACLAM, as an AAALAC council member, and as chair of the AVMA Animal Welfare Committee. A sought-after speaker, published author, and editorial board member, a few of Steven’s accolades include the Iowa State University’s Stange Award for Meritorious Service in Veterinary Medicine, the Charles River Prize in Laboratory Science and Medicine, and the AALAS Charles A. Griffin and Nathan R. Brewer Lifetime Achievement Awards.
BARRY LEVINSON, PhD
Barry’s track record of accomplishments in pharmaceuticals and biotech spans more than 40 years. Prior to co-founding Fidelis, he served as Vice President of Business Development at Valeant Pharma (now Bausch Health) and was a founding Vice President (business development) and Chief Scientific Officer at Aton Pharma. His talent and expertise in recognizing new medical uses and spearheading R&D to expand indications was evident at Aton.
Intrigued with entrepreneurship early in his career, Barry began his corporate years at the biotech startup Ecogen. From there, he spent a decade in increasingly senior positions in cardiovascular research and business development for Schering A.G.’s Berlex Labs (now Bayer Healthcare Pharmaceuticals).
After earning his BA in biochemistry with highest honors from Princeton, Barry went on to earn his MS and PhD degrees in molecular biophysics and biochemistry from Yale University.
SUSAN WITHAM
Susan holds a BS degree in biology from Bridgewater College in Virginia.
We’re committed to leading the industry with quality-driven therapeutics.